Last updated: February 20, 2026
What Is NDC 00173-0547?
NDC 00173-0547 corresponds to Aflibercept Injection, marketed under the brand name Eylea. It is indicated for treating neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), macular edema following retinal vein occlusion (RVO), and certain myopic choroidal neovascularization cases.
Market Size and Demand Drivers
Current Market Landscape
- The global intravitreal anti-VEGF market was valued at approximately $6.4 billion in 2021[1].
- The segment for aflibercept (Eylea) sales accounts for roughly 60% of this market.
- The U.S. market is the largest, accounting for over 50% of global sales**[2].
Key Growth Shifts
- Rising incidence of AMD, DME, and RVO is driving demand.
- Aging populations increase prevalence of target indications.
- Advancements in delivery techniques improve treatment adherence.
Competitive Landscape
| Product |
Market Share (2022) |
Annual Sales (2022) |
Indications |
Price Range (per injection) |
| Eylea (aflibercept) |
60% |
$2.8 billion |
AMD, DME, RVO, myopic CNV |
$1,900 - $2,100 |
| Lucentis (ranibizumab) |
30% |
$1.4 billion |
AMD, DME, RVO |
$2,000 - $2,200 |
| Beovu (brolucizumab) |
10% |
$500 million |
AMD |
$1,500 - $1,700 |
Market Growth Projections
- Compound Annual Growth Rate (CAGR) for the anti-VEGF market is expected at 4-6% through 2027[3].
- Demand for aflibercept is projected to grow at approximately 4.5% CAGR over the next five years, driven by increased treatment rates and expanding indications.
Price Projections
Historical Pricing Trends
- Price per injection in the U.S. has remained relatively stable from 2018 to 2022, fluctuating between $1,900 and $2,100.
- Wholesale acquisition cost (WAC) addresses list price, but actual payer prices vary due to rebates and discounts.
Future Price Outlook
- Short-term (up to 2025): Prices are expected to remain within current historical ranges, assuming no significant policy or approval changes.
- Long-term (2025 and beyond): Prices may decrease marginally due to biosimilar entrants or new competition, with potential reductions of 5-15% over five years.
Impact of Biosimilars
- Biosimilar development for aflibercept is progressing; FDA approvals are anticipated within next 2-3 years.
- Biosimilar pricing could reach 20-30% below originator prices[4].
Cost-Containment Factors
- Payer incentives, including prior authorization and formulary restrictions, influence net prices.
- Value-based pricing models could further pressure prices in the future.
Regulatory and Pricing Policies
- The FDA approved Eylea for multiple indications from 2011 onward.
- The U.S. Medicare Part B reimburses based on the average sales price (ASP) plus a 4.3% markup.
- Policy shifts aiming at reducing drug costs could include increased biosimilar uptake and active price negotiations.
Summary of Market and Price Outlook
| Aspect |
Current Status |
Projection |
| Market size (2022) |
~$2.8 billion (U.S. only) |
~$4.2 billion globally (by 2027) |
| Market growth rate |
4-6% CAGR |
4.5% CAGR |
| Price per injection (2018-2022) |
$1,900 - $2,100 |
Stable short-term, slight decline long-term |
| Biosimilar impact |
In development, potential launch |
20-30% price reduction if launched |
Key Takeaways
- The aflibercept segment dominates intravitreal anti-VEGF therapies with a stable market share.
- Market growth is driven by increasing prevalence of retinal diseases and aging global populations.
- Price stability has persisted, but biosimilar entries could lead to substantial reductions.
- Payer policies and regulatory developments influence pricing trends and market access.
- Long-term projections indicate moderate growth with potential downward pressure on prices.
FAQs
1. How will biosinilar competition affect aflibercept prices? Biosimilars expected within 2-3 years could reduce prices by 20-30%, affecting margins and revenue.
2. Are there upcoming indications that could expand the market? Yes, ongoing research into aflibercept for new retinal conditions and longer dosing intervals could expand indications.
3. How does the pricing in the U.S. compare to other markets? The U.S. generally has higher per-injection costs compared to Europe, partly due to reimbursement and pricing policies.
4. What factors could accelerate price decreases? Increased biosimilar adoption, policy reforms, and value-based pricing models.
5. What is the estimated market share of Eylea globally? It holds approximately 60% of the anti-VEGF market, with variations across regions.
References
[1] Grand View Research. (2022). Intravitreal Anti-VEGF Market Size, Share & Trends Analysis.
[2] IQVIA. (2022). U.S. Pharmaceutical Market Reports.
[3] BCC Research. (2021). Anti-VEGF Market Outlook.
[4] FDA. (2022). Biosimilar Product Approvals and Development Pipeline.
